ESMO - Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer – 2005

Authors : ESMO Guidelines Task Force

References

Levels of evidence (I – V) as used by American Society of Clinical Oncology

Grade

Grade of recommendation (A - D) as used by American Society of Clinical Oncology

Coverage

These recommendations cover Diagnosis, Staging and Risk Assessment, Treatment of both localised and metastatic disease and follow-up.

With respect to treatment, examples of the recommendations include:

• For localised prostate cancer (T1-4NXM0) – treatment options include watchful waiting, radical prostatectomy, brachytherapy, external beam radiotherapy and anti-androgen therapy. Patients should be informed of the potential benefits and harms of the different treatment options before a final decision is taken.
  
  
• In intermediate or high risk or locally advanced (T2-T4) prostate cancer - androgen suppression before and during external beam radiotherapy or following it significantly improves local control, reduces disease progression and improves overall survival.
  
  
• For metastatic prostate cancer – medical castration with LHRH analogues should be accompanied with an anti-androgen for 4 weeks.
  

Source

Annals of Oncology 2005; 16 (Supplement 1): i34 – i36